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Abstract 
CD1d-restricted natural killer T (NKT) lymphocytes are known as potent early 
regulatory cells of immune responses, acting as a bridge between innate and adaptive 
immunity. While invariant NKT (iNKT) cells have a protective role in many tumor 
models, their ability to promote intestinal inflammation, known to enhance intestinal 
cancer, raised the question if they would be protective in intestinal tumor development. 
In this thesis we aimed to define the regulatory role of iNKT lymphocytes in the 
immune response to intestinal tumors, and explore iNKT cell directed immunotherapy 
in this disease. In the first section we have investigated the natural regulation by iNKT 
cells of intestinal tumor formation. ApcMin/+ mice were used as a mouse model for 
colorectal cancer (CRC) in these studies. By crossing ApcMin/+ mice with two different 
iNKT cell deficient mouse strains, we demonstrated that the absence of iNKT cells 
markedly decreased the total number of intestinal polyps in ApcMin/+ mice. Results 
from mechanistic studies suggest that iNKT cells promote intestinal polyps by 
enhancing the activity of regulatory T cells specifically in polyps, promoting a switch 
to a suppressive (M2) macrophage phenotype, and suppressing antitumor TH1 
immunity. In the second section we performed preclinical therapeutic studies with 
different iNKT cell ligands to determine whether this treatment could subvert the 
tumor enhancing function of iNKT cells and result in suppressed tumor development. 
We demonstrate that iNKT cell directed immunotherapy prevented the tumor 
enhancing function of NKT cells leading to a reduction of tumor growth. Further, a 
treatment combining the iNKT ligand α-GalCer with PD-1/PD-L1/2 immune 
checkpoint blockade succeeded to further reduce polyp development.  
In summary, this thesis demonstrates that iNKT cells naturally promote intestinal 
tumor development, by enhancing immunoregulation and suppressing TH1 anti-tumor 
immunity. In contrast, iNKT cell directed immunotherapy combined with immune 
checkpoint blockade led to a reduction of tumors. This prompts further exploration of 
iNKT cell directed immunotherapy in intestinal cancer.  
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